Currently Dyadic is advised in scientific matters by:

Dr. Lerner is Professor of Immunochemistry, Chair in Chemistry, and President of The Scripps Research Institute, one of the largest private, non-profit scientific research organizations in the world. Its staff includes 288 principal investigators, 775 postdoctoral fellows, 230 graduate students, and more than 1,500 technical and administrative staff. Among the senior staff, fourteen are members of the National Academy of Sciences and three are Nobel laureates. The Scripps Research Institute has recently announced plans to establish a major science center in Palm Beach County, Florida, focusing on biomedical research, technology development, and drug design.

Dr. Lerner is a world renowned expert in the field of catalytic antibodies, a field that takes as its principle goal an understanding of how the binding energy of proteins can be utilized to facilitate chemical transformations. Richard Lerner graduated from Northwestern University and Stanford Medical School and received his postdoctoral training at Scripps Clinic and Research Foundation in experimental pathology. Dr. Lerner has received numerous honors, including election to the National Academy of Sciences and the Royal Swedish Academy of Sciences, and receipt of the Wolf Prize in Chemistry.

Dr. Barbas is a Professor of The Scripps Research Institute, Departments of Molecular Biology and Chemistry and The Skaggs Institute for Chemical Biology. He holds the Janet and W. Keith Kellogg II endowed Chair in Molecular Biology and Chemistry. Dr. Barbas has received honours including the Investigator Award from the Cancer Research Institute, The Scholar Award of the American Foundation for AIDS Research, and the Presidential Green Chemistry Challenge Award. He is the author of over 200 scientific articles and is a named inventor on 32 issued U.S. patents. Key accomplishments in the area of biotechnology pioneered by Dr. Barbas and his colleagues include the development of the first human antibody phage libraries, development of the first synthetic antibodies, the development of the first artificial transcription factors capable of regulating endogenous genes, and chemically programmed antibodies-the CovX core technology. Dr. Barbas received his Ph.D. in Organic Chemistry from Texas A&M University.

Dr. Demain has been in the forefront of industrial microbiology and biotechnology for over four decades and has been involved in the research and commercialization of a number of fermentation based pharmaceutical processes. He is currently a Fellow at Drew University's Charles A. Dana Institute for Scientists Emeriti. Previously, Dr. Demain was at the Massachusetts Institute of Technology (MIT) for 32 years, where he most recently served as Professor of Industrial Microbiology in the Department of Biology. Before going to MIT, Dr. Demain spent fifteen years at Merck & Co., where he held various positions in R&D and management focused on fermentation microbiology. His leadership in the area of fermentation is evidenced by over 470 publications, 10 books of which he is coeditor or coauthor, 20 U.S. patents and his election to the presidency of the Society for Industrial Microbiology in 1990, membership in the National Academy of Sciences in 1994, the Mexican Academy of Sciences in 1997 and the Hungarian Academy of Sciences in 2001. Dr. Demain received his Ph.D. in Microbiology from University of California.

Dr. Fink is a founding Member of the Whitehead Institute and American Cancer Society Professor of Genetics at MIT. He served as Director of the Whitehead Institute from 1990 to 2001. Dr. Fink received his Ph.D. in genetics from Yale University, conducted postdoctoral research at the National Institutes of Health and served for 15 years on the faculty of Cornell University. He is a past President of the Genetics Society of America, a Member of the National Academy of Sciences, a Fellow of the American Academy of Arts and Sciences, a Member of the Institute of Medicine, a Member of the Medical Advisory Board of the Howard Hughes Medical Institute and a non-resident Member of the Salk Institute. Among his many honors and awards are the National Academy of Sciences / U.S. Steel Foundation Award in Molecular Biology, the Medal of the Genetics Society of America, the Hansen Foundation Award for Microbiological Research and the Yale Science and Engineering Award. He received the first honorary doctorate awarded by Cold Spring Harbor Laboratory in 1999.

Dr. Fink is a world renowned expert in the field of molecular genetics and cell biology of brewers' yeast and Candida. He leads research into common baker’s yeast to explore critical pathways in cell growth and metabolism. The applications of this research include cancer research and the development of new anti-fungal drugs.

The Whitehead Institute (http://www.whitehead.mit.edu) is a non-profit, independent research and teaching institution recognized worldwide for leading edge programs in genomics, cell biology, cancer research, structural biology, and infectious disease. The Whitehead Institute is affiliated with the Massachusetts Institute of Technology in its teaching activities, but is wholly responsible for its own research programs, governance, and finance.

Dr. Peter J. Punt has been a staff scientist in molecular genetics at TNO Nutrition and Food Research Institute in the Netherlands since 1983. He has worked at TNO as a project leader since 1992 - and more recently as workgroup leader - in the department of Applied Microbiology and Gene Technology. Dr. Punt has co-authored more than 40 peer-reviewed scientific papers and three published patents.

Dr. Punt obtained his M.Sc. in Biology from Leiden University in 1984, and his Ph.D. in Molecular Genetics from Amsterdam University in 1992.

Dr. Sinitsyn has worked with Moscow State University since 1974, first as a researcher, then as a senior researcher, and most recently as the head of its Laboratory of Physical Chemistry of Enzymatic Transformation of Polymers. His scientific expertise includes enzymology, biochemistry, microbiology, and genetics of carbohydrases (cellulases and xylanases), proteases, lipases, esterases, and other enzymes for application in textiles and detergents, pulp and paper, food and animal feed, and other industrial uses.

Dr. Sinitsyn is a member of the Russian National Research Program on Enzyme Engineering Council. He has co-authored 270 publications in Russian and international scientific journals, as well as more than 20 Russian and three international patents. Dr. Sinitsyn received his Ph.D. in Enzymology and Dr. of Sciences in Enzymology and Biochemistry from Moscow State University.

Dr. Cees van de Hondel is a professor in gene technology of filamentous fungi at Leiden University, as well as the head of fungal research in the department of Molecular Genetics at TNO. He is the coordinator of several large multinational projects involving fungal research within the European Community programs. Dr. van den Hondel has co-authored over 80 peer-reviewed scientific papers and eight published patents.

Dr. van den Hondel obtained his MSc in Biochemistry from Utrecht University in 1971, and his PhD in Biochemistry from Nijmegen University in 1976.

Dr. Villafranca has served as Executive Vice President, Pharmaceutical Development and Operations at Neose Technologies, Inc., since February 2004. He joined Neose in October 2002 as Senior Vice President, Pharmaceutical Development and Operations. From 1992 to 2002 he held various positions at Bristol-Myers Squibb, serving most recently as Vice President of Biologics Strategy and Biopharmaceuticals Operations. Prior to Bristol-Myers, Dr. Villafranca spent 20 years at Penn State University, including eight years as the Evan Pugh Professor of Chemistry. Dr. Villafranca earned a B.S. in Chemistry from the State University of New York and a Ph.D. in Biochemistry/Chemistry from Purdue University. He completed his post-doctoral training in Biophysics at the Institute for Cancer Research in Philadelphia.